Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06186765 · ClinicalTrials.gov registry record · NA
F15 Recharge Free Axonics SNM System Clinical Study
A NA study of Urinary Urge Incontinence (UUI) and Urinary Frequency (UF), sponsored by Axonics.
- Active
- Registry status
- NA
- Development phase
- 144
- Enrollment target
- 16
- Study locations
NCT06186765: Active NA study of Urinary Urge Incontinence (UUI) and Urinary Frequency (UF), sponsored by Axonics.
NCT06186765 is a NA study of Urinary Urge Incontinence (UUI) and Urinary Frequency (UF) that is active but no longer recruiting, run by Axonics. The registered enrollment target is 144 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower). The trial reports 16 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06186765, a NA study of Urinary Urge Incontinence (UUI) and Urinary Frequency (UF), is active but no longer recruiting, sponsored by Axonics.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 144 participants
- Enrollment target
- 16
- Study locations
Study Summary
Multicenter, prospective, non randomized, single arm evaluation of patients with overactive bladder (OAB) and/or fecal incontinence (FI) employing the Axonics recharge free SNM System.
Primary Outcome
International Consultation on Incontinence Questionnaire Overactive Bladder Quality of Life (ICIQ-OABqol): questions in each subscale are scored by a summed range of 0 to 100, with a higher score indicating better quality of life. Overall score ≥ 10 points from baseline to follow-up is indicative of a clinically meaningful improvement.
Conditions Studied
Interventions
- DEVICE Axonics SNM System (Model 4101)
Study Locations (16)
Other
- Erasmus Medical Center - Rotterdam
- Queen Elizabeth Hospital - Birmingham
- Bristol Urological Institute - Bristol
- University College London Hospital - London
- Northern General Hospital - Sheffield
Florida
- Florida Gulf Clinical Research - Bradenton
- East Coast Institute of Research - Jacksonville
- Florida Bladder Institute - Naples
Connecticut
- Hartford Healthcare - Waterford
Georgia
- Atrium Health - Macon
Minnesota
- Minnesota Urology - Coon Rapids
Nebraska
- Adult Pediatric Urology & Urogynecology - Omaha
New York
- Columbia University Medical Center - New York
Oregon
- The Oregon Clinic - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 144 participants |
| Start Date | 2023-12-08 |
| Est. Completion | 2027-03 |
| Phase | NA |
What the registry record for NCT06186765 still lists
NCT06186765 is an interventional study that assigns participants to a tested intervention. The registered 144 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower).
The record links to 3 conditions, with Urinary Urge Incontinence (UUI) appearing as the primary indexed condition, and to 1 intervention - of which Axonics SNM System (Model 4101) is the first listed.
NCT06186765 lists 16 locations in 10 states (Other, Florida, Connecticut).
Frequently Asked Questions
What is clinical trial NCT06186765 about?
NCT06186765 is a clinical study titled "F15 Recharge Free Axonics SNM System Clinical Study". Multicenter, prospective, non randomized, single arm evaluation of patients with overactive bladder (OAB) and/or fecal incontinence (FI) employing the Axonics recharge free SNM System.
What is the current status of trial NCT06186765?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 144 participants. The study started on 2023-12-08. Estimated completion is 2027-03.
What conditions does trial NCT06186765 study?
This clinical trial studies the following conditions: Urinary Urge Incontinence (UUI), Urinary Frequency (UF), Fecal Incontinence (FI).
What interventions are being tested in trial NCT06186765?
The interventions under investigation include: Axonics SNM System (Model 4101) (DEVICE).
Who is sponsoring clinical trial NCT06186765?
This trial is sponsored by Axonics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06186765 being conducted?
This trial has 16 study locations across Connecticut, Florida, Georgia, Minnesota, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Urinary Urge Incontinence (UUI)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06186765's enrollment target sits among peer trials
144 706th of 2000 higher than 1,290 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01861106 · 144 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations
- NCT03482245 · 144 participants · NA
The Role of Circadian Clock Proteins in Innate and Adaptive Immunity
- NCT03504683 · 144 participants · NA
MEAL TIMING Study: Effect of Time-Restricted Feeding on 24-hour Glycemic Control, Blood Pressure, and Cardiovascular Disease Risk Factors in Adults With Prediabetes
- NCT03905603 · 144 participants · Early Phase 1
Relative Contributions of Predictors of Hyperandrogenism in Older vs. Young Women With PCOS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI